This Adriamycin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line to increasing concentrations of doxorubicin in-vitro. L929/A cells can be used in the development of novel anti-cancer treatments. Resistance can be circumvented by modulating agents such as verapamil and quinine. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.
Quick Search
Products 
